Introduction
Hematopoietic stem cells (HSCs) undergo self-renewing divisions to sustain life-long hematopoiesis. HSC self-renewal is regulated by networks of proto-oncogenes and tumor suppressor genes. 1 During leukemogenesis, genetically altered HSCs play an important role in initiating and/or maintaining leukemia phenotypes. 2, 3 These mutant HSCs often gain a competitive advantage over wild-type HSCs through increased cell division. In most cases, increased HSC proliferation tends to be associated with reduced HSC self-renewal and subsequently HSC depletion. 4 In contrast, increased HSC cycling is associated with normal or increased self-renewal in HSCs deficient for p53 5, 6 or p18INK4c. 7, 8 Thus, it remains unclear how the proliferation and self-renewal of HSCs are differentially regulated during leukemogenesis.
Ras proteins are master signaling switches that couple extracellular stimuli to the intracellular response machinery. Oncogenic RAS mutations are prevalent in essentially all human cancers. 9 In human leukemias, although both NRAS and KRAS are mutated at significant frequencies, oncogenic NRAS mutations are significantly more prevalent than oncogenic KRAS mutations. 10 In mice, expression of one copy of oncogenic Nras (Nras G12D/1 ) from its endogenous locus in hematopoietic cells leads to expansion of myeloid progenitors, increased long-term reconstitution of bone marrow (BM) cells, and a chronic myeloproliferative neoplasm (MPN) after a prolonged latency. [11] [12] [13] However, acute expression of Nras G12D/1 in a pure C57BL/6 background does not induce hyperactivated granulocyte macrophage colony-stimulating factor signaling or increased proliferation in myeloid progenitors. 13 In contrast to Nras G12D/1 , stronger activation of oncogenic Ras signaling, such as Kras G12D/1 and two copies of oncogenic Nras (Nras   G12D/G12D ), leads to hyperactivated cytokine signaling, hyperproliferation, and expansion of myeloid progenitors as well as an acute MPN. 2, 3, 13, 14 It is thus unclear how Nras G12D/1 induces expansion of myeloid progenitors and promotes MPNs. We hypothesized that Nras G12D/1 promotes leukemogenesis by aberrantly regulating HSC function.
Here, we show that endogenous Nras G12D/1 induced proliferation and increased self-renewal and myeloid differentiation bias in HSCs. ERK1/2 is constitutively hyperactivated in Nras G12D/1
HSCs, and downregulation of MEK/ERK signaling attenuates Nras G12D/1 HSC phenotypes.
Materials and methods

Mice
Cre expression was induced through intraperitoneal injection of 250 mg (Sigma-Aldrich) or 7. , but not more committed myeloid progenitors, efficiently initiated CMML-like phenotypes in primary recipients, and only CMML cells containing HSCs could re-establish the disease in secondary recipients (supplemental Table 1 ). These data indicate that Nras G12D/1 HSCs are required to initiate and maintain CMML-like phenotypes in recipient mice and thus serve as MPN-initiating cells. Similar observations are reported in human chronic lymphocytic leukemia 16 and in a mouse model of BCR-ABL-induced chronic myelogenous leukemia, 17 suggesting a common role of genetically altered HSCs in the chronic phase of leukemias. Noticeably, CMML-like phenotypes that developed in the secondary recipients required a long latency similar to that observed in the primary recipients, suggesting that just as in Kras G12D/1 -initiated MPNs, 2 additional mutations promoting CMML development did not occur in Nras G12D/1 HSCs. With the second hits, we believe that myeloid progenitors gain short-term self-renewal capability but are not fully transformed to CMML-initiating cells, which explains why these cells fail to maintain disease phenotypes in secondary recipient mice.
Nras
G12D/1 increases HSC proliferation and self-renewal capability
We further investigated how endogenous oncogenic Nras signaling regulates HSC function to promote leukemogenesis. We first examined the HSC compartment in Mx1-Cre; Nras G12D/1 mice (described in Wang et al 11 ) at different time points after pI-pC injections. The conditional Nras G12D allele was recombined in almost 100% of HSCs in these mice, although the recombination frequency was 0% to 35% in Mx1-Cre; Nras G12D/1 mice without pI-pC treatment (supplemental Figure 1) . The day of the first pI-pC injection is referred as day 1. On days 5 and 12 ( Figure 1A ), 18 compared with control HSCs, Nras G12D/1 HSCs displayed a moderate but consistent expansion (;25% increase). We did not observe pI-pC-induced Sca1 expression in total BM cells or defined HSCs (supplemental Figure 2) . The numbers of multipotent progenitors (MPPs) and LSK cells in G12D/1 mice were also significantly elevated compared with controls ( Figure 1B-C) .
Expression of endogenous Nras
G12D/1 increased the division of HSCs, but not whole BM (WBM) cells. On day 12, consistent with a previous report, 19 only ;0.5% of control HSCs were in S/G 2 /M. In contrast, a significant increase of Nras G12D/1 HSCs was detected in S/G 2 /M, suggesting an increased proliferation in these HSCs ( Figure 1D and supplemental Figure 3A ). This result was further confirmed by using 5-ethynyl-29-deoxyuridine (EdU) in vivo incorporation ( Figure 1E and supplemental Figure 3B ). We noticed that the increased proliferation in Nras G12D/1 HSCs is moderate compared with the strong hyperproliferation of Kras G12D/1 HSCs. 20 To determine whether the proliferation of Nras G12D/1 HSCs was correlated with increased HSC self-renewal, we transplanted highly purified control or Nras G12D/1 HSCs along with wild-type WBM cells into lethally irradiated mice ( Figure 1F Figure 4A) . We euthanized some of the recipients 16 weeks posttransplant. Control donor HSCs represented ;25% of the recipients' BM HSC compartment, and Nras G12D/1 HSCs comprised .90% ( Figure 1F ). On the basis of our quantitative analysis, a single Nras G12D/1 HSC generated ;10-fold as many HSCs as a single control HSC. Secondary transplantation further supported the increased self-renewal potential in Nras G12D/1 HSCs ( Figure 1G and supplemental Figure 4B ). These results indicate that Nras G12D/1 signaling enhances HSC self-renewal capability. The increased self-renewal potential in Nras G12D/1 HSCs is in sharp contrast to reduced self-renewal and depletion in HSCs expressing stronger oncogenic Ras, such as Kras G12D/1 or Nras G12D/1G12D 21 (G.K., Y.-I.C., and Jing Z., unpublished data), suggesting a distinct regulation of HSC function in an oncogenic Ras activity-dependent manner.
Nras G12D/1 hyperactivates ERK1/2 in HSCs
To investigate the signaling mechanism(s) underlying aberrant Nras G12D/1 HSC function, we studied the MEK/ERK and AKT signaling in HSCs and their downstream MPPs 22 ( Figure 2A ) by using a recently developed HSC phospho-flow method. 23 In the absence of serum and cytokines, ERK1/2 was constitutively hyperactivated in Nras G12D/1 HSCs (twofold over control HSCs) but not in MPPs (Figure 2A) . The constitutive hyperactivation of ERK1/2 was inhibited by AZD6244, a potent MEK inhibitor (supplemental Figure 5) . In contrast, AKT activation in Nras G12D/1 HSCs and MPPs was comparable to that in controls (Figure 2A ). Upon stimulation with interleukin-3, ERK1/2 was further hyperactivated in Nras G12D/1 HSCs but not in MPPs ( Figure 2B ). The hyperactivation of ERK1/2 in Nras G12D/1 HSCs is in sharp contrast to the normal pERK1/2 level in Nras G12D/1 MPPs and Lin 2 cKit 1 progenitor cells, 13 indicating that HSC is the most sensitive cell type to oncogenic Nras mutation.
Gene set enrichment analysis (GSEA) identifies a gene signature associated with myeloid differentiation in Nras G12D/1 HSCs
To better understand the molecular mechanisms underlying oncogenic Nras signaling-induced aberrant HSC function, we performed a microarray analysis (accession number: GSE46948) using highly purified HSCs. Compared with control HSCs, Nras G12D/1 HSCs did not show significant differential expression in genes or pathways that are associated with HSC self-renewal 4 (supplemental Figure 6A-B) . congeneic BM cells into lethally irradiated mice. Donor-derived blood cells were regularly analyzed in the peripheral blood of recipients. Donor-derived HSCs were quantified in recipients 16 weeks after transplantation. (G) 2 3 10 6 BM cells isolated from primary recipients were transplanted into lethally irradiated secondary recipient mice. Donorderived blood cells were regularly analyzed in the peripheral blood of secondary recipients. Data are presented as mean 1 standard deviation. *P , .05; **P , .01; ***P , .001.
org From
Because Nras G12D/1 HSCs support leukemia development predominantly in myeloid cells (supplemental Table 1 and Wang  et al   11   ) , we sought to determine whether these HSCs are associated with a myeloid differentiation bias. In support of this idea, GSEA of our HSC microarray results identified a gene signature associated with myeloid differentiation in Nras G12D/1 HSCs (supplemental Figure 6C) . Consistent with the GSEA results, the common myeloid progenitor (CMP) compartment was greatly expanded in Nras G12D/1 mice ( Figure 2E , Li et al, 12 and Wang et al 13 ), although common lymphoid progenitor (CLP) compartment was comparable to that in control mice (supplemental Figure 6D) . Our current result of myeloid differentiation bias in Nras G12D/1 HSCs explains the selective expansion of myeloid progenitor compartment in Nras G12D/1 mice, in which granulocyte macrophage colony-stimulating factor signaling and cell proliferation are indistinguishable from those in control cells. 24 an efficacious and specific MEK inhibitor ( Figure 2C ). AZD6244 prevented the expansion of Nras G12D/1 HSC and CMP compartment ( Figure 2D -E) and restored slightly enlarged spleen to a normal size in Nras G12D/1 mice (supplemental Figure 7) . In addition, we generated Nras G12D/1 ; Erk2 1/2 mice to downregulate the MEK/ERK signaling using a genetic approach. Loss of one copy of Erk2 partially downregulated ERK signing (supplemental Figure 8) and significantly decreased the cycling of Nras G12D/1 HSCs without affecting the cycling of WBM cells ( Figure 2F ). The slightly enlarged spleen remained a similar size (supplemental Figure 9) .
In summary, our data suggest that moderate activation of oncogenic Ras/MEK/ERK signaling contributes to the increased longterm competitiveness in mutant HSCs during leukemogenesis.
